Philogen's Quiet Hand: A $300M War Chest and a 20-Year Bet on Interleukin-12

H1 2026 update: Nidlegy nears an EMA decision, but the genuinely new thing is dodekin and the intraCORP delivery platform.

PHIL.MI · Earnings Call · 2026-09-25

A biotech that no longer needs the market's money

Most small-cap biotech updates are a funding story wearing a science costume. Philogen's first-half 2026 call is the opposite. CEO Dario Neri opened the financial section himself and let the number do the talking: “If we look at the cash, we went from EUR 64 million in 2024 to EUR 100 million in 2025 to more than EUR 300 million in 2026.” — Dario Neri, CEO · 2026-09-25 That is not trial-progress cash — that is licensing cash, a step-change driven by the deal struck around Bristol Myers Squibb's RayzeBio for the OncoACP3 radiopharmaceutical. Asked point-blank whether second-half burn would offset it, Neri was unhurried: “as a CEO, I feel very comfortably with the cash situation that we have and with the cash that we expect in the near future.” — Dario Neri, CEO · 2026-09-25 With the equity trading around a EUR 900 million market cap, the balance sheet is now a material slice of the story. A company that can start four new clinical programs in 2027 without tapping shareholders has optionality its peers lack.

Dodekin and intraCORP — the genuinely new thing

The most important change this quarter is the elevation of dodekin, an L19 antibody fused to interleukin 12, from pipeline footnote to centerpiece. Management gave it real airtime. Dose escalation is complete — 0.1 up to 12 mcg/kg — and an expansion cohort is running. Neri described the signal plainly: “We have seen, for example, a patient with a heavily pretreated disease, so metastatic mucosal melanoma... we saw a strong metabolic complete response.” — Emanuele Puca, Investor Relations or Communications · 2026-09-25The mechanism is the story. IL-12 has been the graveyard of immuno-oncology for two decades — Roche and others tried it, hit toxicity, and walked away. Neri frames his work as a deliberate counterpoint: “we have really spent 20 years perfecting the molecule. We have seen molecules go to the clinic and fail... We believe we will be the first, actually, to formally prove this.” — Dario Neri, CEO · 2026-09-25 The vehicle for that proof is a patented trick called intraCORP technology: a short-acting JAK inhibitor, ruxolitinib, given transiently to mask IL-12 activity exactly when blood concentrations peak — defusing toxicity while leaving the tumor-bound payload, which builds up over time thanks to the antibody, untouched. It only works because the payload is targeted; a non-targeted IL-12 could never be rescued this way.

What we want to do is to use an intracellular signaling inhibitor, namely ruxolitinib, to transiently mask the activity of IL-12 for only a short time when its blood concentrations are the highest without impacting on the antitumor efficacy as the inhibitor gets cleared.
Emanuele Puca, Investor Relations or Communications · 2026-09-25

The clever part: intraCORP is a platform, not a molecule. Neri confirmed it has already been demonstrated for IL-2 and TNF and could itself be licensed — a rare case of a small biotech pitching a royalty layer on top of a royalty layer.

A strategic split is now visible

There is a genuine tension inside this pipeline, and the call exposed it. Philogen licensed OncoACP3 to RayzeBio early and now defers all questions on it; the clear cell-adjacent asset is gone. But on OncoCAIX, the kidney-cancer imaging ligand, Neri is openly reluctant to let go: “we have multiple companies that have actually approached us for a possible licensing of the product. Never say never... when we have them in-house, we like to move product with Philogen quality, Philochem quality, and also with Philochem speed.” — Dario Neri, CEO · 2026-09-25 That is the pivot worth watching: a company once defined by antibody-cytokine fusions now leans heavily on its small-molecule Philochem arm — radiopharmaceuticals targeting FAP, CA9 and ACP3 — and is deciding how much of it to keep. This is the transition from a single-mechanism shop to a platform house, and the partnering choices are where it will show up first.

Where Philogen sits versus the tape

The broad market this quarter is fixated on one thing: tariff-refund mechanics and their second-order reinvestment effects, with a parallel cluster around AI data centers. Philogen is orthogonal to both — a European oncology name whose catalysts are regulatory dates and clinical readouts, not trade policy. Its nearest sector signal comes not from the megacaps but from biotech peers reporting in the same window: PureTech's High Risk MDS and STRIDE program language, Oxford Biomedica's late-stage gene-therapy readouts. The overlap is thin — this remains a company-unique narrative.The one consensus theme Philogen genuinely engages is the melanoma competitive set. Cesare Colombo asked Neri to separate Nidlegy from Moderna's personalized vaccine, and Neri drew the map carefully: “We focus on Stage III disease. They focus in Stage II and Stage IV.” — Dario Neri, CEO · 2026-09-25 He folded in Replimune, the intralesional oncolytic-virus player that just won FDA approval in late-line disease — a reminder that immunotherapy in and around non-melanoma skin cancer is heating up on all sides. Nidlegy's own footing rests on registrational trials with recurrence-free survival as the primary endpoint, and on an EMA submission already clocking toward feedback late this year.

The takeaway

Nothing dramatic broke this quarter — no surprise dataset, no price shock (the tape here is thin and silent, offering the analyst little to lean on). What changed is emphasis. Philogen is now a cash-rich company with a fresh lead asset in dodekin, a defensible platform in intraCORP, a portfolio of registrational trials, and a partnering decision it is deliberately deferring. That is a different animal from the Philogen of prior quarters. The interesting question is no longer whether it can fund the science — it plainly can — but which pieces it eventually decides to keep.